New drug hailed as ‘gamechanger’ in tackling stubbornly high blood pressure | High blood pressure

Doctors greet a new pill for patients with high blood pressure with the current drug -resistant high blood pressure.

Globally, more than 1.3 billion people have hypertension. In half of them, high blood pressure is uncontrolled or resistant to existing treatments. The risk of heart attack, stroke, kidney disease and premature death is much higher.

Now a new drug that breaks box office records – baxdrostat – trials have been shown to significantly reduce blood pressure in those who remain dangerous, although they receive a few drugs.

The results of the BAXHTN study, which contain 796 patients from 214 clinics worldwide, saw that the blood pressure of patients receiving baxdrostat after 12 weeks has fallen about 9-10 mmHG (millimeter mercury, blood pressure measurement unit).

The drug reached healthy blood pressure levels than 1 mg (39.4%) or 2mg (40%) – less than 10 (18.7%) on the placebo.

Stubbornly the details of the breakthrough against high blood pressure, the world’s largest heart conference Madrid in the European Cardiology Association Congress appeared. The results of the hearing, which was sponsored by Astrazeneca, were published in the New England Magazine Medical Magazine.

The main researcher Prof Bryan Williams, the head of UCL Medical President, said: “In BaxHTN FAZ-3, it is exciting to obtain a decrease in cystolic blood pressure with Baxdrostat with Baxdrostat, because this reduction depends on the risk of heart attack, heart, heart attack and child disease.

“I think this may be a gamechanger in our difficult to control or difficult to control blood pressure. The results show that this drug can globally help half a billion people.”

The breakthrough received decades of research.

Blood pressure is strongly affected by a hormone called aldosterone, which helps to regulate the salt and water balance of the kidneys. Some people produce too much aldosterone and cause the body to adhere to salt and water. This aldosterone irregularity pushes the blood pressure up and makes it very difficult to control.

The fight against Aldosterone irregularity has been the main objective of research for many years, but it is impossible to achieve so far. Baxdrostat works by preventing aldosterone production and directly deals with this drive of this high blood pressure.

“This drug development is really scientific discovery victory,” he said at the conference in Madrid.

“Aldosterone is a well -known hypertension driving force, but for decades, scientists have fought to precisely prevent production. Baxdrostat is one of the first therapies to make it selectively. [blood pressure] Decreases in uncontrolled or resistant hypertension. “

Historically, it has been reported that richer Western countries have greatly increased in high blood pressure levels. However, due to the varying diets, the number of people living with hypertension is now much higher in east and low -income countries. More than that Half of the affected live in AsiaIt includes 226 million people in China and 199 million in India.

Professional Paul Leeson, a cardiologist and professor of cardiovascular medicine at Oxford University, who was not involved in the study, said the pill could be a “valuable additional treatment için to cope with high blood pressure.

“We had drugs that could prevent aldosterone work for many years, but in fact, aldosterone levels are not lower, so patients may still have negative effects of matter.

“BAXDROSTAT… A version of a new range of drugs that employees different and directly reduces aldosterone levels.

“More importantly, the trial was carried out in several countries and included patients of different ethnic origin as well as men and women. This helps to ensure that the findings are related to blood pressure problems and the patient range we see.”

Separately, doctors in Madrid were told that a Jab that exploded cholesterol, which was applied twice a year, had the potential to transform heart care.

New trial data presented at the conference were recommended Leqvio is also known as Inclisiran And they helped patients with Novartis to meet cholesterol goals faster than other treatments. Patients also experienced less muscle pain, widespread side effects of statins, drugs lowering drugs.